Key result
Study successfully synthesizes and characterizes six potential impurities observed during bulk carvedilol synthesis.
Why the study?
Impurities formed during the bulk synthesis of carvedilol were observed but not previously synthesized or characterized.
Key points are not available for this paper at this time.
Design
Synthesis and characterization study of impurities
Answers are grounded in this paper and cite their sources.
May aid carvedilol impurity profiling in manufacturing; extends reference standards for pharmaceutical quality research.
Carvedilol (Coreg) is a nonselective β-adrenergic blocking agent with vasodilating activity. It is used for the treatment of congestive heart failure and hypertension. During the bulk synthesis of carvedilol, we have observed six impurities: Imp-I, Imp-II, Imp-III, Imp-IV, Imp-V, and Imp-VI. The present work describes the synthesis and characterization of these impurities.
No takes yet. Share an insight, caveat, or question.
Rao et al. (2010) studied this question. Six potential impurities (Imp-I to Imp-VI) observed during the bulk synthesis of the antihypertensive drug carvedilol were successfully synthesized and characterized.
Synapse has enriched 10 related papers. Consider them for comparative context: